Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Sandoz Inc.

www.us.sandoz.com

Latest From Sandoz Inc.

RFID Tags Found To Improve Drug Supply Chain Tracking In Recent DSCSA Pilot

A pilot that used RFID tags with 2D barcodes was touted as more effective than using 2D barcodes alone in tracking drugs through the supply chain.

Manufacturing Quality

What’s Next? Five Things To Look Out For In August

Second-quarter earnings results from two of the Big Three – Teva and Mylan – hold much of the intrigue in August, while more competition in the nascent Avastin biosimilar market could materialize in Europe.

Sales & Earnings Generic Drugs

Taro Penalties Exceed $400m As It Admits Fixing Prices With Sandoz

In the latest development arising from ongoing generic pricing investigations in the US, Taro has admitted to fixing prices, allocating customers and rigging bids for generic medicines, under a conspiracy with multiple firms, including Sandoz.

Deals Legal Issues

Biocon Sees Recovery In Biosimilars

Biocon’s biosimilars business sees bounce-back in first quarter of fiscal 2021, with the US business witnessing gradually improving demand. The Indian company also sees potential for improved affordability in the US.

Biosimilars Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
UsernamePublicRestriction

Register